Home
Solutions
Resources
About
Contact
Book a Demo
Home
Solutions
Overview
AIxURO
AIxTHY
coming soon
AIxPAP
coming soon
AIxPUL
coming soon
Resources
About
Contact
Contact us
A Vision to Transform
Healthcare through AI
Our vision is more than an idea. It's a tangible roadmap to transforming cancer diagnosis and monitoring through our smart computational cytology platform.
This solution aids critical decision support during clinical diagnosis and monitoring to:
Improve clinical outcomes
Reduce healthcare burdens
Operating at the Intersection of Computer Science and Healthcare
In 2018, AIxMed's founders blended their divergent, respective backgrounds to break through the traditional cytology status quo. Samuel Chen brings AI technology ingenuity and leadership experience from ASUS and Compal. Dr. Tien-Jen Liu offers medical expertise as a trained physician and serial medtech entrepreneur.
Their combined diversity of thought will make a meaningful impact in healthcare, with intuitive commercialized tools to simplify clinical workflows and richly strengthen the quality of healthcare.
About Our AI Technology
Targeted Experience Means Impactful Solutions
AIxMed unites noted leaders from multiple disciplines to positively impact cytopathology diagnosis. We are creating a ripple effect that extends from laboratories through to patients. Our software and AI technologies are developed at the leading edge:
  • Medicine and Healthcare - first-hand experience in patient care, laboratory methods, healthcare trends, regulations and policies.
  • Diagnostic Tool Development - identifying specific market needs and commercializing widespread solutions.
Experienced Digital Cytology Management Team
We have united noted leaders from computer science, cytopathology, and diagnostic systems development to bring a meaningful change to cytology.  Our team includes executive leaders, physicians, award-winning cytopathologists and leaders including contributing authors of The Paris System (TPS) for Reporting Urinary Cytology.  Together, we are creating the future of cytology by bringing forward abnormal cells including their respective quantitative information to improve reporting and patient care.

AIxMed. Beyond Human (in)sight.
Samuel Chen
Chief Executive Officer, President & Co-Founder
View bio
Tien-Jen Liu, M.D.
Chief Operating Officer & Co-Founder
View bio
Stephen Hess
SVP Business Development
View bio
Barbara Crothers, D.O.
Chief Scientist
View bio
Accomplished Advisory Board
Dr. HJ Chang
  • Chairman & CEO, Taiwan Global BioFund
  • Former Deputy Minister, Dept of Health, Taiwan
Dr. Judy Chou
  • President and CEO, AltruBio
  • Former SVP/Global Biotech Head/Berkeley Site Head, Bayer Pharmaceutical
Ms. Laura Housman
  • Chief Commercial & Operations Officer, Olaris, Inc.
  • Former Head/VP, Access Outcomes and Population Health, Exact Sciences
  • Adjunct Faculty, Massachusetts College of Pharmacy and Health Sciences
Mr. Shawn Marcell
  • President/CEO, Bifrost Biosystems
  • Entrepreneur In Residence/Visiting Scholar, Wyss Institute, Harvard
Dr. Liron Pantanowitz
  • Chair, Department of Pathology, UPMC
  • President, Digital Pathology Association (DPA)
  • President, American Society of Cytopathology
Dr. Yuh-Geng Tsay
  • Venture Partner, VIVO Capital
  • Former President/SVP Immunodiagnostics, Thermo Fisher Scientific
Dr. Vincent S. Tseng
  • IEEE fellow
  • Chair Professor, Department of Computer Science, National Yang Ming Chiao Tung University, Taiwan
Dr. Christopher VandenBussche
  • Associate Professor of Pathology at The Johns Hopkins University School of Medicine
  • Associate Director, Cytopathology Division at Johns Hopkins Hospital
Ms. Fran White
  • Founder and President Emerita of MDC Associates, IVD Regulatory Affairs
Join Our Newsletter
Join the revolution
Subscribe to our newsletter to receive the latest updates from AlxMed.
Copyright © 2019-2025 AIxMed, Inc.
For Research Use Only. Not for use in diagnostic procedures.
Privacy Policy
•
Terms  & Conditions
•
Legal Info
For Research Use Only. Not for use in diagnostic procedures.
Samuel Chen
Chief Executive Officer, President & Co-Founder
Bringing over 25 years of software development experience to the team, Samuel Chen is the president and CEO of AIxMed. He was the Vice President of Software Development at Trend Micro and helped establish the company as one of the top three information security companies in the world and Taiwan’s #1 software company. Additionally, Mr. Chen held executive leadership roles at ASUSTek and Compal and founded the Compal AI Lab. Mr. Chen graduated from National Chiao-Tung University and attained a Master’s of Science degree in computer science from the University of Southern California.
Tien-Jen Liu, M.D.
Chief Operating Officer & Co-Founder
Tien-Jen Liu, MD, is an experienced attending physician with a proven history in the biotechnology industry. Dr. Liu is skilled in clinical research, medical device development, clinical study, and business development. He is also the director of the biomedical innovation program at a medical university.
Stephen Hess
SVP Business Development
Steph Hess is an experienced business development professional bringing two decades of IVD and life science experience to the team in both Product and Business Development. He has consulted for dozens of start-up companies and helped introduce multiple products to the market. Mr. Hess was previously VP Global Business Development at Invetech and VP Global Sales and Marketing at IDEX Health and Science. Steph obtained an Engineering Degree from Rutgers University and a Master’s of Science degree in Management from WPI.
Barbara Crothers, D.O.
Chief Scientist
Dr. Crothers is an internationally-recognized cytopathologist and co-editor of The International System for Reporting Serous Cytopathology with over 30 years of active- duty military experience as a leader in pathology and cytopathology. Prior to joining AIxMED, she was a senior consultant pathologist at the Joint Pathology Center, the premier reference center for the Department of Defense and Veteran’s Administration. She is board-certified in Anatomic & Clinical Pathology and Cytopathology. She has served as the President, American Society of Cytopathology (ASC); Pathology Consultant to the Army Surgeon General; Chair of the College of American Pathologist’s (CAP) Cytopathology Committee; Pathology Program Director; Chief, Department of Pathology; and Cytopathology Medical Director. She has received numerous professional, military and academic honors and awards, most recently the ASC’s Papanicolaou Award for lifetime achievement.